Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209

Article  PubMed  Google Scholar 

Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–861

Article  CAS  PubMed  Google Scholar 

Wu Y, Zheng Q, Zou B, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis. Hepatol Int. 2020;14(2):259–269

Article  PubMed  Google Scholar 

Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69(4):896–904

Article  PubMed  Google Scholar 

Zhang X, Wu M, Liu Z, et al. Increasing prevalence of NAFLD/NASH among children, adolescents and young adults from 1990 to 2017: a population-based observational study. BMJ Open. 2021;11(5):e042843

Article  PubMed  PubMed Central  Google Scholar 

Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739–752

Article  PubMed  Google Scholar 

Joseph P, Leong D, McKee M, et al. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circ Res. 2017;121(6):677–694

Article  CAS  PubMed  Google Scholar 

Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors 1990–2019: update from the GBD 2019 study. J Am College Cardiol. 2020;76(25):2982–3021

Article  Google Scholar 

Andersson C, Vasan RS. Epidemiology of cardiovascular disease in young individuals. Nat Rev Cardiol. 2018;15(4):230–240

Article  PubMed  Google Scholar 

Xin Du, Patel A, Anderson CS, et al. Epidemiology of cardiovascular disease in China and opportunities for improvement: JACC international. J Am College Cardiol. 2019;73(24):3135–3147

Article  Google Scholar 

Global Cardiovascular Risk Consortium. Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med. 2023;389(14):1273–1285

Article  Google Scholar 

Lee H, Lee YH, Kim SU, et al. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19(10):2138-2147.e10

Article  PubMed  Google Scholar 

Zhou XD, Targher G, Byrne CD, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023;17(4):773–791

Article  PubMed  Google Scholar 

Guerreiro GTS, Longo L, Fonseca MA, et al. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD? Hepatol Int. 2021;15(2):380–391

Article  PubMed  Google Scholar 

Toh JZK, Pan XH, Tay PWL, et al. A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022;20(11):2462-2473.e10

Article  CAS  PubMed  Google Scholar 

Oh YH, Jeong S, Park SJ, et al. Reversal of nonalcoholic fatty liver disease reduces the risk of cardiovascular disease among Korean. Medicine (Baltimore). 2023;102(44):e35804

Article  CAS  PubMed  Google Scholar 

Park J, Kim G, Kim H, et al. The associations between changes in hepatic steatosis and heart failure and mortality: a nationwide cohort study. Cardiovasc Diabetol. 2022;21(1):287

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cui H, Liu Q, Wu Y, et al. Cumulative triglyceride-glucose index is a risk for CVD: a prospective cohort study. Cardiovasc Diabetol. 2022;21(1):22

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cui H, Liu Q, Zhao Z, et al. Interacting and joint effects of triglyceride-glucose index and blood pressure on cardiovascular diseases risk: a prospective cohort study. Diabetol Metab Syndr. 2024;16(1):188

Article  CAS  PubMed  PubMed Central  Google Scholar 

Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612

Article  PubMed  PubMed Central  Google Scholar 

Li Y, Wu S, Gao J, et al. Association of stroke with metabolic dysfunction-associated fatty liver disease with and without CKD. Am J Kidney Dis. 2024;83(4):477–488

Article  CAS  PubMed  Google Scholar 

Woodward M. Rationale and tutorial for analysing and reporting sex differences in cardiovascular associations. Heart. 2019;105(22):1701–1708

Article  PubMed  Google Scholar 

Walli-Attaei M, Rosengren A, Rangarajan S, et al. Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study. Lancet. 2022;400(10355):811–821

Article  PubMed  Google Scholar 

Liu S, Wang J, Wu S, et al. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: a prospective analysis. Metabolism. 2021;120:154779

Article  CAS  PubMed  Google Scholar 

Zheng M, Wang X, Yin Y, et al. New-onset age of metabolic-associated fatty liver disease and incident cardiovascular diseases: findings from prospective cohort. The Innov Med. 2024;2(2):100064

Article  Google Scholar 

Zeng J, Yang RX, Sun C, et al. Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. World J Gastroenterol. 2020;26(15):1792–1804

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feldman A, Eder SK, Felder TK, Kedenko L, Paulweber B, Stadlmayr A, et al. Clinical and metabolic characterization of lean caucasian subjects with non-alcoholic fatty liver. Am J Gastroenterol. 2017;112(1):102–110

Article  PubMed  Google Scholar 

Rastogi A, Rath I, Varadarajan A, Ramakrishna G, Bihari C, Maiwall R. Non-alcoholic fatty liver disease (NAFLD) in lean individuals - Single centre large cohort clinicopathologic and immunophenotypic study. Pathol Res Pract. 2022;238:154112

Article  CAS  PubMed  Google Scholar 

Souza M, Diaz I, Al-Sharif L. Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals. Hepatol Int. 2024 Aug 8.

Nabi O, Lapidus N, Boursier J, de Ledinghen V, Petit JM, Kab S, et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study). Hepatology. 2023;78(1):272–283

Article  PubMed  Google Scholar 

Ha J, Yim SY, Karagozian R. Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(10):2496-2507.e5

Article  PubMed  Google Scholar 

Alarabi M, Pan Z, Romero-Gómez M, George J, Eslam M. Telomere length and mortality in lean MAFLD: the other face of metabolic adaptation. Hepatol Int. 2024 Jun 20.

Raj D, Tomar B, Lahiri A, et al. The gut-liver-kidney axis: novel regulator of fatty liver associated chronic kidney disease. Pharmacol Res. 2020;152:104617

Article  CAS  PubMed  Google Scholar 

Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol. 2022;18(1):55–66

Article  CAS  PubMed  Google Scholar 

Younossi ZM, Zelber-Sagi S, Henry L, et al. Lifestyle interventions in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2023;20(11):708–722

Article